Mithra huldigt zijn nieuw ontwikkelings- en productiecentrum in Flémalle

  • Vandaag viert Mithra de officiële inhuldiging van zijn CDMO , in aanwezigheid van de heer Jean-Claude Marcourt, Vicepresident van de Regering, minister van Economie, Industrie, Innovatie en Digitalisering.
  • De inhuldiging van het gebouw betreft Fase I van het project, de productie-infrastructuur voor polymeervormen, implantaten en steriele “injectables”.
  • Momenteel produceert de CDMO de eerste zgn. “technical batches” van het kandidaat-product Myring, een hormonale vaginale anticonceptiering.
  • De CDMO is bedrijfsklaar met drie maanden voorsprong op het oorspronkelijke schema. Op dit moment wordt verder gewerkt aan Fase II van het project, de ”tabletting” productieruimte. Mithra bevestigt bovendien dat het project binnen het vooropgestelde budget blijft.
  • De opening van de Mithra CDMO leidt, tegen het eind van 2016, tot de creatie van 54 nieuwe banen. Bovendien dient uiteraard nog extra personeel aangeworven worden naarmate de projecten zich verder ontwikkelen.

Het persbericht lezen

Mithra Will Propose Christiane Malcorps as new Independent Board Member / Phase III Clinical Study for Estelle® in us Launched With First Randomized Patient

Liège, Belgium, 23rd September 2016 –Today, Mithra announces that Christiane Malcorps will be proposed as a new member of Mithra’s Board of Directors (Mithra SA) during the next Shareholders meeting. She also is appointed as member of the Board of Mithra’s CDMO (Development and production center).

Liège, Belgium 23rd September 2016 – Mithra announces today that the first patient has been randomized in the American Phase III clinical trials for its Estetrol-based product candidate Estelle® (E4/DRSP). The enrollment of this first patient marks the official launch of the Estelle® (E4/DRSP) Phase III clinical trial in United States. With this, the Phase III is fully in line with the timing and objectives announced in the Prospectus.

Download the press release

The Contraception Journal Publishes a Scientific Paper on the Haemostatic Effects of Estetrol; Results Are Encouraging for the Estelle® Product Candidate

  • Mithra Pharmaceuticals announces today the publication of a scientific paper highlighting the reduced haemostatic effects of the Estetrol (E4)/Drospirenone (DRSP) combination, namely the Estelle® product candidate developed by Mithra, in a comparative study with another combined oral contraceptive.
  • The published results are particularly interesting for the scientific community, as they suggest a low procoagulant effect of the E4/DRSP combination that should be clinically verified for low antithrombotic consequences.
  • The Contraception Journal is an international journal on reproductive health ranked among the best publications in the fields of obstetrics and gynaecology. The Contraception Journal is well-known among worldwide specialists and serves as a reference in the medical sphere.

Liège, Belgium, 8 September 2016 – Mithra Pharmaceuticals announces today the publication of a paper in the peer-reviewed Contraception Journal.

Read the press release

Mithra Pharmaceuticals Announces its First Half 2016 Financial Results and Operational Progress

Liège, Belgium 1 September 2016, 07h30 – Mithra Pharmaceuticals, a leader in Women’s Health market, today announced its consolidated financial results for the six-month period ending 30 June 2016 prepared in accordance with article 13 of the Royal Decree of 14 November 2007. The full interim financial report (regulated information) is available on our website in the Investors section.

Read the press releaseDownload the report